Michael J. Konkel
Michael J. Konkel has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Hermogenes Jimenez
Lundbeck Research USA, Inc., 215 College Road, Paramus, NJ 07652, USA
2 shared publicationsMary W. Walker
Lundbeck Research USA, Inc., 215 College Road, Paramus, NJ 07652, USA
2 shared publicationsBharat Lagu
Lundbeck Research USA, Inc., 215 College Road, Paramus, New Jersey 07652, and Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105
1 shared publicationBrian E. Kornberg
Lundbeck Research USA, Inc., 215 College Road, Paramus, New Jersey 07652, and Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105
1 shared publicationGamini Chandrasena
Lundbeck Research USA, Inc., 215 College Road, Paramus, New Jersey 07652, and Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105
1 shared publicationHeather Coate
1 shared publication
Latest Publications
- 1 August 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (15) , 3950-3954
Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility
- 1 August 2006
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (15) , 3950-3954
Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility
- 1 June 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (13) , 3757-3758
3-Arylimino-2-indolones Are Potent and Selective Galanin GAL3 Receptor Antagonists
A series of 3-imino-2-indolones are the first published, high-affinity antagonists of the galanin GAL3 receptor. One example, 1,3-dihydro-1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-2H-indol-2-one (9), was shown to have high affinity for the human GAL3 receptor (Ki = 17 nM) and to be highly selective for GAL3 over a broad panel of targets, including GAL1 and GAL2. Compound 9 was also shown to be an antagonist in a human GAL3 receptor functional assay (Kb = 29 nM).
- 1 June 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (13) , 3757-3758
3-Arylimino-2-indolones Are Potent and Selective Galanin GAL3 Receptor Antagonists
A series of 3-imino-2-indolones are the first published, high-affinity antagonists of the galanin GAL3 receptor. One example, 1,3-dihydro-1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-2H-indol-2-one (9), was shown to have high affinity for the human GAL3 receptor (Ki = 17 nM) and to be highly selective for GAL3 over a broad panel of targets, including GAL1 and GAL2. Compound 9 was also shown to be an antagonist in a human GAL3 receptor functional assay (Kb = 29 nM).